Redhill Biopharma Ltd. - ADR
RDHL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.69M
Close$
$0.85
70.5% upside
Current Fair Value
70.5% upsideUndervalued by 70.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.69 Million |
|---|---|
| Enterprise Value | $-1,207,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 4.9 |
| Outstanding Shares | 1,803,001 |
Return
| Return on Equity | -218.21% |
|---|---|
| Return on Assets | -36.74% |
| Return on Invested Capital | -133.64% |
Valuation & Multiples
| P/E Ratio | -3.97 |
|---|---|
| PEG | -11.73 |
| Price to Sales | 0.1 |
| Price to Book Ratio | 0.25 |
| Enterprise Value to Revenue | -0.13 |
| Enterprise Value to EBIT | 0.15 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.89 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
$-435.00
Average shareholder expectationRevenue Estimate
$22.70 M
Average shareholder expectationNext Earnings Call
Expected Date
March 18, 2027
EPS Estimate
$-474.29
Average shareholder expectationRevenue Estimate
$24.51 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Redhill Biopharma
CEO: Dror Ben-Asher